TREE: Immunotherapy After Radiotherapy in Elderly ESCC

The Central Hospital of Lishui City (Other)
Overall Status
Not yet recruiting ID

Study Details

Study Description

Brief Summary

The incidence and mortality of esophageal squamous cell carcinoma are at the forefront in China.Most part of patients are elderly. Concurrent chemoradiotherapy is the standard treatment for unresectable locally advanced esophageal squamous cell carcinoma. Most elderly patients cannot tolerate concurrent chemotherapy because of complications and other reasons. Immunotherapy has definite efficacy and low toxicity in advanced esophageal squamous cell carcinoma, and the results combined with radiotherapy have also been preliminarily reported. Therefore, it is necessary to further explore the efficacy and safety of radiotherapy combined with immunotherapy in elderly patients with esophageal squamous cell carcinoma.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

This is a prospective, multicenter, single-arm, phase Ⅱ clinical study to evaluate the efficacy and safety of radiotherapy alone followed by sequential injection of Toripalimab in elderly patients with unresectable esophageal squamous cell carcinoma who could not accept concurrent chemotherapy.

Study Design

Study Type:
Anticipated Enrollment :
30 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
Toripalimab After Radiotherapy Alone in Elderly Esophageal Squamous Cell Carcinoma: A Prospective Phase II Clinical Trial
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Apr 30, 2024
Anticipated Study Completion Date :
Jun 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Radiotherapy Sequential Toripalimab

Radiotherapy:Intensity-modulated radiotherapy (IMRT) Immunotherapy: Toripalimab

Radiation: Radiotherapy
95% PGTV56-60Gy/28-30 fractions, 2Gy/1 fractions; 95% PTV50.4-54Gy/28-30 fractions, 1.8Gy/1 fractions; 5 days a week; 6 weeks.
Other Names:
  • Intensity-modulated radiotherapy (IMRT)
  • Drug: Toripalimab
    Toripalimab (200 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision
    Other Names:
  • Immunotherapy
  • Outcome Measures

    Primary Outcome Measures

    1. Progression-free survival (PFS) [2 years]

      We aim to evaluate the progression-free survival (PFS) of elderly patients with unresectable esophageal squamous cell carcinoma who were unable to accept concurrent chemotherapy and received sequential treatment with Triptolide injection after radiotherapy alone.

    Secondary Outcome Measures

    1. Overall survival (OS) [2 years]

      Overall survival (OS) is defined as the time from treatment to death, regardless of disease recurrence .

    2. Objective response rate (ORR) [2 years]

      Objective response rate (ORR) is defined as the proportion of patients with a complete response(CR) or partial response(PR) to treatment according to RECIST v1.1.

    3. Duration of response (DOR) [2 years]

      Duration of response (DOR) was determined from date of initial response to PD according to RECIST v1.1.

    4. Time to death or distant metastasis (TTDM) [2 years]

      Time to death or distant metastasis (TTDM) according to RECIST v1.1.

    Eligibility Criteria


    Ages Eligible for Study:
    75 Years and Older
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    1. Age ≥75 years old, regardless of gender;

    2. Esophageal cancer confirmed by histology or cytology;

    3. Unresectable, unable to tolerate or refuse surgery and concurrent chemoradiotherapy;

    4. Unable to tolerate chemotherapy;

    5. There are at least one lesions measurable according to RECIST 1.1;

    6. Stage II-iva (AJCC 8 TNM classification)

    7. Endoscopic ultrasonography confirmed that esophageal lesions did not invade adjacent organs (T1-4a).;

    8. ECOG PS 0-1;

    9. Forced expiratory volume (FEV) >0.8 liter;

    10. Life expectancy of at least 12 weeks;

    11. Have not received any anti-tumor treatment for esophageal cancer in the past, including radiotherapy, chemotherapy, surgery, biotherapy,etc.

    12. Has sufficient organ function: (1) Blood routine: ANC≥1.5×109/L; PLT≥50×109/L; HGB≥90 g/L((No blood transfusion and blood products within 14 days, no use of G-CSF and other blood-stimulating factors to correct)) (2) Liver function: TBIL ≤ 1.5 × ULN,ALT、AST ≤2.5 × ULN, (3) Renal function: Cr≤1×ULN or crcl ≥50 ml/min (4) Adequate haemostasis laboratory data prior to randomization: INR or PT ≤1.5×ULN (If the subject was receiving anticoagulant therapy, as long as the PT was within the intended use range of anticoagulant drugs) (5) Myocardial enzymes were within the normal range.

    13. Patients voluntarily joined this study, signed informed consent and provided diagnosis and treatment data after cancer diagnosis before entering the group, good compliance, and cooperation with follow-up visits;

    Exclusion Criteria:
    1. Synchronous or metachronous second primary malignancy. Participants with basal cell carcinoma of the skin, or cervical cancer in situ that have undergone potentially curative therapy are not excluded from the study;

    2. with multifocal primary esophageal cancer;

    3. The pathological diagnosis was esophageal small cell carcinoma, adenocarcinoma, or mixed carcinoma.

    4. Esophageal squamous cell carcinoma with active bleeding within 2 months of the primary lesion;

    5. Patients whose imaging has shown that the tumor has invaded the important blood vessels or the investigator judges that the tumor is likely to invade the important blood vessels and cause fatal hemorrhage during the follow-up study

    6. The patient has any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, glomerulonephritis, thyroiditis (patients with vitiligo or asthma has been completely relieved in childhood, and do not need any intervention during adulthood can be included; patients with type I diabetes with good insulin control can also be included; hypothyroidism caused by autoimmune thyroiditis requiring hormone replacement therapy can also be included)

    7. Clinically significant cardiac disease or impaired cardiac function, such as: MeanQT interval corrected for heart rate (QTc) ≥470 ms, Congestive heart failure requiring treatment (New York Heart Association [NYHA] grade > 2), left ventricular ejection fraction (LVEF) <50% as determined by Echocardiography.

    8. Active infection or fever of unknown origin > 38.5 ° C during screening or before the first dose (tumor-related fever, as judged by the investigator, was eligible);

    9. Current pneumonitis or interstitial lung disease or history of pneumonitis or interstitial lung disease.

    10. Has had congenital or acquired immunodeficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV-DNA ≥ 104 copies/ml) or hepatitis C (HCR-RNA was higher than the detection limit of the analytical method);

    11. Previous treatment with another PD-1, PD-L1;

    12. Known hypersensitivity to macromolecular protein preparations or to any anti-PD-1 antibody component;;

    13. Immunosuppressive drugs used within 7 days prior to the initial study treatment, excluding local glucocorticoids, or systemic glucocorticoids at physiological doses (i.e., no more than 10 mg/ day of prednisone or equivalent doses of other glucocorticoids); Systemic steroid doses of less than 10 mg of prednisone daily or its equivalent are allowed in patients receiving physiologic replacement steroid doses without autoimmune disease.

    14. if they had undergone major surgery patients must have fully recovered from surgery with no major ongoing safety issues before the experiment begins.

    15. Currently participating in an interventional clinical research treatment, or has received another investigational drug or used an investigational device within 4 weeks prior to the first administration of the drug.

    16. Live vaccine within 4 weeks prior to first dose (Cycle 1, Day 1); NOTE: Injectable inactivated viral vaccine against seasonal influenza is allowed; however, live attenuated influenza vaccine for intranasal administration is not allowed.

    17. The investigator considers it unsuitable for inclusion. Patients with uncontrollable seizures or loss of self-control due to mental illness. serious abnormal laboratory test results, family, or social factors, which may affect the safety of the subjects or the data collection.

    Contacts and Locations


    No locations specified.

    Sponsors and Collaborators

    • The Central Hospital of Lishui City


    • Principal Investigator: Zhifeng Tian, M.D, Lishui Municipal Central Hospital,Zhejiang,China

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    The Central Hospital of Lishui City Identifier:
    Other Study ID Numbers:
    • ZJLSRT-001
    First Posted:
    Mar 30, 2023
    Last Update Posted:
    Mar 30, 2023
    Last Verified:
    Mar 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Keywords provided by The Central Hospital of Lishui City
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 30, 2023